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This study aimed to assess the mean sojourn time (MST) of prostate cancer, to estimate the probability of overdiagnosis, and to
predict the potential reduction in advanced stage disease due to screening with PSA. The MST of prostate cancer was derived from
detection rates at PSA prevalence testing in 43842 men, aged 50–69 years, as part of the ProtecT study, from the incidence of non-
screen-detected cases obtained from the English population-based cancer registry database, and from PSA sensitivity obtained from
the medical literature. The relative reduction in advanced stage disease was derived from the expected and observed incidences of
advanced stage prostate cancer. The age-specific MST for men aged 50–59 and 60–69 years were 11.3 and 12.6 years, respectively.
Overdiagnosis estimates increased with age; 10–31% of the PSA-detected cases were estimated to be overdiagnosed.
An interscreening interval of 2 years was predicted to result in 37 and 63% reduction in advanced stage disease in men 65–69 and
50–54 years, respectively. If the overdiagnosed cases were excluded, the estimated reductions were 9 and 54%, respectively. Thus,
the benefit of screening in reducing advanced stage disease is limited by overdiagnosis, which is greater in older men.
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Prostate cancer is the most frequently diagnosed cancer in men
and the second leading cause of cancer death in men in the
industrialised world (Zhu et al, 2006). The value of screening using
prostate-specific antigen (PSA) testing is still controversial (Ilic
et al, 2006), nevertheless there is considerable asymptomatic PSA
testing in developed countries. To quantify the likely benefits and
harms of various PSA testing regimens is relevant to an under-
standing of the natural history of the disease. A crucial parameter
in early detection is the sojourn time, the period in which the
tumour is asymptomatic but detectable by screening. This
indicates the upper limit of time by which diagnosis is advanced
by screening (lead time). Accurate estimation of sojourn time
facilitates inference on the optimum interval between screens, the
likely effectiveness of screening, and the extent of overdiagnosis.
Conceptually, overdiagnosis is the diagnosis due to screening,
which would not have led to a clinical diagnosis during the lifetime
of the host had screening not taken place (Paci et al, 2004).
Mean lead times and sojourn times due to PSA screening have
been estimated in retrospective studies that used stored blood
samples obtained from individuals who were later clinically
diagnosed with prostate cancer (Stenman et al, 1994; Auvinen
et al, 2002) and in simulation studies (Draisma et al, 2003; Telesca
et al, 2008). However, there are no analytic estimates obtained
directly from screening data, and there are no estimates from the
United Kingdom. The only published UK study on overdiagnosis,
reported tentative overdiagnosis estimates attributable to increa-
sed diagnostic PSA testing rather than to screening, using
estimates of lead time from the literature (Pashayan et al, 2006).
In this study we use empirical data to estimate the age-specific
mean sojourn time (MST), the subsequent likelihood of over-
diagnosis, and the predicted potential relative reduction in
advanced stage disease following screening at different intervals.
These estimates are derived from prevalence screen-detected cases
and incidence of clinical cases using biostatistical and epidemio-
logical methodology, without formal mathematical modelling.
MATERIALS AND METHODS
Data on prevalent cases were obtained from the Prostate Testing
for Cancer and Treatment (ProtecT) study, an ongoing national
study of community-based PSA testing and randomised trial of
subsequent prostate cancer treatment (Donovan et al, 2003).
Prostate-specific antigen testing in the context of the Protect study
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detected cases as PSA-detected cases.
In the ProtecT study, approximately 200000 men between the
ages of 50 and 69 years, ascertained through randomly selected
general practices in nine regions in the United Kingdom, were
invited for enrolment. Men with concomitant or past malignancies
or other major comorbidities that precluded enrolment in the
treatment trial were excluded. Consenting eligible men were
offered a PSA test. A PSA level of 3.0ngml
 1 was used as the
threshold for further investigation. All men with PSA X3.0ngml
 1
were offered transrectal, ultrasound-guided biopsy using a 10-core
lateral biopsy template. Pathologic evaluation was carried out by
specialist uropathologists in each centre. All laboratories have
participated in the UK National External Quality Assessment
Service programme for PSA testing (Donovan et al, 2003).
Data on clinically detected prostate cancer cases were obtained
from the Office for National Statistics. These data included number
of registered cases in England by year of registration and 5-year
age group between 2002 and 2005. Mid-year population estimates
for England for each year from 2002 to 2005 by 5-year age groups
were obtained from the Office for National Statistics. Age-specific
incidence of clinical prostate cancer per 10
5 person years was
calculated. Individual-based data with information on clinical
stage and histological grade were obtained from the Eastern
Cancer Registry and Information Centre (ECRIC) – population-
based cancer registry in the East of England.
Prostate cancer was classified as localised disease with tumour–
node–metastasis (TNM; Sobin and Wittekind, 1997) stage T2 and
below; and regional-distant (advanced stage) disease with TNM
stage T3 and above.
Statistical analysis
The mathematical details and the relevant formulae are given
below. Our broad strategy, however, was as follows:
(1) Stratified by age, estimate the MST of prostate cancer, taking
account of sensitivity of testing, which we derived from the
literature.
(2) By combination of (1) with national statistics on death rates by
age, estimate the proportion of overdiagnosed tumours by age
and testing frequency, that is, those tumours, which would not
have become symptomatic before the host died of other
causes.
(3) From the sojourn time estimates, calculate the expected
proportions of screen-detected and interval cancers by age
and PSA testing frequency.
(4) From the stage distribution of PSA-detected tumours in
ProtecT and those in the general population, combined with
the results of (3) above, estimate the likely reduction in
advanced stage disease by age and testing frequency.
(5) Adjust the estimates in (4) by subtracting overdiagnosed cases
from the early disease cases (although we estimate over-
diagnosis from overall incidence, to obtain conservative
estimates of the benefit of PSA testing, we assume that all
overdiagnosed cases are localised stage).
The sensitivity of PSA test
The sensitivity of the PSA test was derived from the literature
(Bretton, 1994; Imai et al, 1994, 1995; Jubelirer et al, 1994; Stenman
et al, 1994; el-Galley et al, 1995; Higashihara et al, 1996; Brett, 1998;
Gustafsson et al, 1998; Hoffman et al, 2002; Mistry and Cable,
2003). Age-specific sensitivity values were estimated using a linear
regression analysis of reported sensitivity on age at testing and
PSA cut-off used, weighted by the number of individuals tested in
each study and age group. A clustered regression analysis was
used, allowing observations from the same study to be correlated,
but assuming independence of observations from different studies.
Mean sojourn time
The mean sojourn time, the average time spent in the preclinical
screen-detectable phase, is assumed to have exponential distribu-
tion (Day et al, 1989). The instantaneous transition rate from
preclinical to clinical disease is l. The inversion of l is the MST. If
S is the sensitivity of the screening test, P is the prevalence of
preclinical disease, and I is the annual incidence of preclinical
disease, then from Paci and Duffy (1991)
P ¼
I:S
l
If the MST is n years, one would expect to anticipate
approximately n years of disease incidence with a single screen
of a population, assuming good sensitivity (Day et al, 1989). As the
incidence of prostate cancer changes with age, for each age at
screen, MST was calculated as the number of years where the
cumulative incidence catches up with the preclinical incidence,
such that as I changes with age, let (1/l)¼n, then we find n
such that
X n
j¼1
Ij ¼
Pj
Sj
where Ij¼incidence in year of life j and j¼1 corresponds to age
at screen.
The 95% confidence intervals (CI) on the MST were estimated
from the 95% CI on P assuming a Poisson distribution of
prevalence and assuming that the sensitivity did not contribute
mutually to the variation.
Probability of overdiagnosis
The probability of overdiagnosis, probability that a PSA-detected
case would have taken longer than the remaining lifetime to
progress to clinical cancer, can be estimated as
e lt
where t is the expected remaining lifetime (Paci et al, 2004). Using
expected remaining lifetimes for the UK male population in 2003–
05, and estimates of age-specific sojourn time, age-specific
probabilities of overdiagnosis were calculated.
The 95% CI on the probability of overdiagnosis were estimated
from the 95% CI values of l.
Relative reduction in advanced stage disease by PSA
screening
Here we define clinical disease as the disease detected in the
absence of screening and preclinical disease as that detected
by screening. Using the approach of Launoy et al (1998), the
probability of diagnosing prostate cancer at screening in a
population subjected to screening (as opposed to the disease
arising clinically as an interval cancer) was derived. This estimate
is often referred to as the programme sensitivity (ps) and depends
on the screening sensitivity, the sojourn time, and the interval
between screens such that
ps ¼
Sð1   e lrÞ
ðlrð1  ð 1   SÞe lrÞ
where r¼interval between screens
The 95% CI on the estimated ps was calculated using the Delta
method.
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stage prostate cancer from the ProtecT and ECRIC databases,
respectively, and the probability of diagnosing prostate cancer at
screening, it is possible to estimate the expected proportion of
localised disease E(pl) following screening. E(pl) is the sum of the
proportion of localised disease detected by screening and the
proportion of localised disease among interval cases
EðplÞ¼ð pls   psÞþð plcð1   psÞÞ
where pls proportion of localised disease detected by screening;
and plc proportion of localised disease detected clinically. We
estimated plc from the ECRIC data. The expected proportion of
advanced disease is E(pa)¼1 E(pl). The relative reduction in
advanced disease following screening is
RRa ¼
EðpaÞ
OðpaÞ
where O(pa) is the observed proportion of advanced disease
detected clinically, also estimated from the ECRIC data. Assuming
that overdiagnosis occurs only in the prevalence screening and
only applies to localised disease, the relative reduction in advanced
disease following screening was estimated after excluding the
proportion of overdiagnosed cases.
The 95% CIs on the expected RRs of advanced stage disease were
calculated using repeated application of the Delta method to the
estimated components, assuming that the proportions with
advanced stage disease were binomially distributed. To render
tractable the estimation of CIs, we had to constrain at least one
estimate as a fixed value and so with PSA test sensitivity as the
published estimates were based on large numbers and the standard
error would therefore have been very small. Further details of the
interval estimation are available from the authors (SD, NP).
RESULTS
The average uptake of PSA testing within ProtecT was 48% in
response to single invitation; 11% of men had an abnormal PSA
result, of whom approximately 12% refused biopsy. Between
1 January 2002 and 31 December 2005, 43842 men were tested. Of
those, 1544 (3.5%) were identified with prostate cancer. Table 1
shows the number of persons tested and cases diagnosed by age
and stage. The mean age (s.d.) of diagnosis was 62.0 (4.9) years. Of
the PSA-detected cancers, 87% were localised. In England, in the
same period, 42850 men, aged 50–69 years, were registered with
clinically detected prostate cancer and 27% of the cases presented
with advanced stage disease (ECRIC data; Table 1).
Appendix A summarises the studies used to derive the
sensitivity of PSA test at cut-off of 3.0ngml
 1. Using these, we
estimated mean sensitivity for the PSA cut-off of 3.0ngml
 1 for
each age group, and from these, the MST by age. Results are shown
in Table 2. The estimated MSTs were 11.3 and 12.6 years for men
aged 50–59 and 60–69 years, respectively.
The probability of overdiagnosis of screen-detected prostate
cancer increased with age, from 10% (95% CI 7–11%) for the age
group 50–54 to 31% (95% CI 26–32%) for the age group 65–69
(Table 3). The lower estimates of overdiagnosis at earlier ages
reflect the greater life expectancy within which the disease could
become symptomatic. Overall, 8 out of 1000 men aged 50–69 years
undertaking PSA testing are likely to be overdiagnosed.
Table 4 shows the estimates of the proportion of prostate cancer
that could be identified at screening, by age group and
interscreening interval. For an interscreening interval of 2 years,
the proportion of cases detected by screening varied from 86 to
92% for the age groups 50–54 to 65–69, respectively. Increasing
the interscreening interval to 10 years, the proportion of cases
identified decreased; 55 and 66% for the age groups 50–54 and
65–69, respectively.
The corresponding estimated relative risks of advanced stage
prostate cancer are shown in Table 5. For different interscreening
intervals, as age increased, the percentage reduction in advanced
stage disease decreased. After accounting for overdiagnosis, the
percentage reduction in advanced stage disease was smaller. The
greatest reductions were estimated for the youngest group, 50–54,
ranging from 34% (95% CI 26–42%) for 10-yearly screening
starting in this age group to 54% (95% CI 41–65%) for 2-yearly
screening. The smallest reductions were seen in the age group 65–
69: 6% (95% CI 2–10%) and 9% (95% CI 0–17%) reduction with
interscreening intervals of 10 and 2 years, respectively. The
reduction in advanced stage disease was more strongly dependent
on the interscreening interval for younger age groups, due to the
lower test sensitivity in these age groups.
In other way, the findings indicate that potentially, 1.4, 1.8, and
2 advanced stage cancers could be avoided per 1000 men, aged
50–69 years, undertaking PSA testing at 10, 5, and 2 years inter-
vals, respectively. After accounting for overdiagnosis, the potential
Table 1 Number of persons screened, prostate cancers detected by age
and stage, including percentages of late stage cases based on the ProtecT
study, and the corresponding percentages for clinical prostate cancers from
the Eastern Cancer Registry and Information Centre (ECRIC), 2002–2005
Age group
Quantity 50–54 55–59 60–64 65–69 Total
Number of persons screened
a 12092 13787 10060 7903 43842
Total cancers detected
a 136 347 498 563 1544
Localised stage cancers detected
a 125 310 430 460 1325
Advanced stage cancers detected
a 9 35 61 95 200
Stage unknown
a 2278 1 9
% Advanced stage (preclinical)
a 6.6 10.1 12.2 16.9 13.0
% Advanced stage (clinical)
b 26.1 22.5 27.9 28.7 26.9
aData derived from ProtecT study.
bData derived from ECRIC.
Table 2 Estimates of sensitivity, mean sojourn time, transition rates, and 95% confidence intervals (CI) by age group, based on prevalence screening
cancers and registered incident clinical cases, England, 2002–2005
Age group
50–54 55–59 60–64 65–69
PSA test sensitivity 0.70 0.76 0.83 0.90
Prevalence of preclinical prostate cancer per 10
5 men 1124.7 2516.9 4950.3 7123.9
Cumulative incidence of prostate cancer per 10
5 person-years
P n
j¼1
Ij ¼ P
S 1606.7 3303.0 5981.4 7897.9
Mean sojourn time (years) (95% CI) 11.3 (10.4–12.2) 11.3 (10.8–12.2) 12.6 (11.8–13.4) 12.6 (11.2–13.5)
Transition rate (preclinical to clinical) (95% CI) 0.088 (0.082–0.096) 0.088 (0.082–0.093) 0.079 (0.075–0.085) 0.079 (0.074–0.089)
Abbreviation: PSA¼prostate-specific antigen.
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and 1 per 1000 PSA-tested men, respectively.
DISCUSSION
There is considerable opportunistic PSA testing activity ongoing in
the developed world. Although randomised trial evidence on the
effect of such testing on mortality from prostate cancer is not yet
available, trials will be reported in the near future. It is therefore
appropriate to address implementation issues such as different
frequencies of testing and the likely benefits and harms, notably
the reductions in advanced disease and the rates of overdiagnosis.
For the latter purposes it is necessary to estimate the sojourn time,
that is, the potential lead time achieved.
We have demonstrated a simple approach to estimate sojourn
time, and overdiagnosis from prevalence screening and population
incidence data. Our method of estimation of the MST takes account
of the changing underlying incidence with age. Our results suggest
that for men aged 50–69 years, the MST of prostate cancer is
between 11.3 and 12.6 years. These findings are in line with
estimates obtained from studies of prevalence to incidence ratios
(Etzioni et al, 1998; Auvinen et al, 2002), and simulation models
(Draisma et al, 2003; Pinsky et al, 2006). Etzioni et al (1998) reported
average sojourn time of 11.6 years using prevalence estimates based
on autopsy studies and the age-specific incidence of clinical disease
from Surveillance Epidemiology, and End Results. Auvinen et al
(2002) estimated mean lead time and then inferred the MST,
assuming that cancers in the first round of screening are detected on
average in the midpoint of the MST. The estimates of Auvinen et al
(2002), based on 292 cases derived from the Finnish screening trial
and expected incidence of prostate cancer, were 14.4 years (based on
age-adjusted expected incidence) and 9.3 years (based on age-
cohort-adjusted expected incidence). Draisma et al (2003), using
microsimulation modelling based on 151 screen-detected cases
derived from the results of the Rotterdam section of the European
Randomised study of Screening for Prostate Cancer (ERSPC),
showed MST of 12.7 years (range 12.1–14.2 years). However,
Draisma et al (2003) estimated the MST as the time from screen
detection to either clinical diagnosis in the absence of screening or
to death by other causes. Pinsky et al (2006) estimated MST of 16
years among the participants of the control arm of the Prostate
cancer Prevention Trial using convolution model; this higher value
could be related to adopted broader definition of clinical cases that
included men with positive digital rectal exam findings.
In our study, MST did not vary with age in the age range 50–69
years. The estimates of MST reported by Auvinen et al (2002), for
the ages at screening between 55 and 67 years, did not vary with
age; the age-specific values ranged from 15.8 to 14.6 years and 9.8
to 8.5 years (depending on the reference rates used). On the other
hand, Etzioni et al (2008) derived simulation-based estimates
showing decreasing MST with age, with estimates of 13.7 years
(range 12.9–14.5 years) for 50–59 years and 9.1 years (range 8.7–
9.6 years) for 60–69 years. This estimate of MST is based on
screen-detected cancers that would progress to clinical disease
within the lifetime of individuals. This could account for the
Table 3 Expected remaining lifetime and probability of overdiagnosis and 95% confidence intervals (CI) by age group
Age group
50–54 55–59 60–64 65–69
Expected remaining lifetime (years)
a 27.3 23.0 18.9 15.2
Probability of overdiagnosis (95% CI) 0.10 (0.07–0.11) 0.15 (0.12–0.15) 0.23 (0.20–0.24) 0.31 (0.26–0.32)
aBased on life table on UK males, 2003–2005, produced by the Government Actuary’s Department.
Table 4 Estimated proportion of prostate cancer to be diagnosed by screening and 95% confidence intervals (CI) by age group for different interscreening
intervals
Proportion of prostate cancer identified by screening
Age group
50–54 55–59 60–64 65–69
10-year screening interval (95% CI) 0.55 (0.52–0.57) 0.58 (0.56–0.59) 0.63 (0.61–0.64) 0.66 (0.63–0.68)
5-year screening interval (95% CI) 0.71 (0.69–0.73) 0.74 (0.73–0.75) 0.78 (0.77–0.79) 0.80 (0.79–0.82)
2-year screening interval (95% CI) 0.86 (0.85–0.87) 0.88 (0.87–0.88) 0.90 (0.90–0.91) 0.92 (0.91–0.92)
Table 5 Predicted relative risk of advanced stage prostate cancer and 95% confidence intervals (CI) by age group and interscreening interval, with and
without accounting for overdiagnosis
Relative risk of advanced stage
50–54 55–59 60–64 65–69
Assuming no overdiagnosis
10-year screening interval (95% CI) 0.60 (0.52–0.70) 0.68 (0.60–0.77) 0.64 (0.58–0.71) 0.73 (0.66–0.81)
5-year screening interval (95% CI) 0.48 (0.38–0.61) 0.59 (0.49–0.70) 0.56 (0.48–0.64) 0.67 (0.59–0.77)
2-year screening interval (95% CI) 0.37 (0.25–0.54) 0.51 (0.40–0.65) 0.49 (0.40–0.59) 0.63 (0.54–0.74)
Accounting for overdiagnosis
10-year screening interval (95% CI) 0.66 (0.58–0.74) 0.77 (0.70–0.83) 0.79 (0.75–0.83) 0.94 (0.90–0.98)
5-year screening interval (95% CI) 0.55 (0.46–0.66) 0.70 (0.62–0.79) 0.74 (0.68–0.80) 0.92 (0.87–0.97)
2-year screening interval (95% CI) 0.46 (0.35–0.59) 0.64 (0.55–0.75) 0.70 (0.64–0.76) 0.91 (0.83–1.00)
Implications of sojourn time on screening
N Pashayan et al
1201
British Journal of Cancer (2009) 100(7), 1198–1204 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yobserved decrease in MST with age. In our study, while estimating
MST we did not exclude overdiagnosed cases. Our slightly longer
estimates of sojourn time in the 60–69 age group are consistent
with the higher prevalence of prostate cancer at older age.
As there will be some asymptomatic PSA testing in the
population, our sojourn times and overdiagnosis rates may be
underestimated. In a sensitivity analysis, based on the findings of
Pashayan et al (2006), we estimated the expected number of men in
England undertaking PSA testing and the proportion of the
prostate cancer diagnosis following PSA testing. Re-estimating
MST, after excluding those cases from the incidence data obtained
from ONS, increased the sojourn time by only 0.1 year. Any bias in
overdiagnosis rates is similarly likely to be small.
Our estimates of MST were derived from prevalence and
incidence data, taking into account the sensitivity of the PSA test
estimated from external data. Simultaneous derivation of the MST
and sensitivity of the PSA test would be preferable. As sensitivity of
PSA could not be derived from the ProtecT study, due to absence
of data on interval cancers, age-specific sensitivity values were
derived from the medical literature. We have estimated an overall
PSA test sensitivity of 80%, which is comparable to Hakama et al
(2007) estimate of 85% using the incidence method and based on
randomised prostate cancer screening trial in Finland.
Published PSA sensitivity values were based on sextant biopsy.
In the ProtecT study, PSA-detected cases were identified with 10-
core biopsy, which is known to have higher detection rate
(Stamatiou et al, 2007). Thus it is likely that the sensitivity values
we have used are underestimates, in which case, the derived MST
values are likely to be overestimates.
Our results suggest that overdiagnosis increases with age, partly
due to our assumption of a homogeneous model of sojourn time
within each age group, and to the fact that the observed prevalence
to incidence ratio was similar in all age groups. Because of this, the
long sojourn time estimated for all age groups means that the older
subjects are more likely to die of other causes before symptomatic
diagnosis. In future we plan to model the sojourn time as a mixture
of populations within each age group. This may give more
substantial overdiagnosis estimates at younger ages.
We estimated that 10–31% of the screen-detected cases would
not have been diagnosed in the absence of screening. Here we have
defined overdiagnosis as the detection of tumours, which would
never have been diagnosed in the absence of screening (Paci et al,
2004). There are other measures, such as the number of tumours
detected, which did not result in saving of life (McGregor et al,
1998). The latter estimate would be a higher proportion of tumours
than that estimated using our definition (Frankel et al, 2003). This
quantity will be the subject of future research on this cohort.
Draisma et al (2003) reported higher estimates (27–47%) for ages
55–67 years, but apply specifically to the 1991 situation in the
Netherlands with respect to clinical detection of prostate cancer.
Telesca et al (2008), defining probability of overdiagnosis for a
screen-detected case as the probability of dying of other causes
during the lead time and using simulation modelling, reported
3–14% overdiagnosis. However, these estimates were for a
simulated mean lead time of 4.5 years.
Our results indicate that with a 2-year screening interval, 85% of
prostate cancer cases could be screen detected. The estimated
benefit from screening, in terms of reducing advanced stage
disease, ranged from 37% at ages 65–69 years to 67% at ages
50–54 years. When excluding overdiagnosed cases, the estimated
benefit was further reduced to 9 and 54% for the age groups 65–69
and 50–54 years, respectively. Etzioni et al (2008), in a population-
based simulation model, projected a 52% decline in distant stage
incidence with PSA screening.
Further research is needed to assess the implications of stage shift
on mortality reduction. ERSPC (Draisma et al,2 0 0 3 ) ,P r o s t a t e ,
Lung, Colorectal and Ovarian Cancer Screening Trial (Andriole
et al, 2005), and the Comparison Arm for ProtecT (Metcalfe et al,
2008) in the upcoming years will provide a definite answer on the
benefits of prostate cancer screening in reducing mortality.
The figures in Table 5 suggest that screening at later ages (in
particular from age 65) may have only a minor effect on incidence of
advanced stage disease after taking overdiagnosis into account.
They also suggest that the frequency of screening becomes less
influential on the incidence of advanced disease with increasing age.
This is apparently a result of poorer screening sensitivity rather than
shorter sojourn time in the younger age groups. Another target for
future research is estimation of the absolute benefit of screening at
different ages, and the absolute incremental benefit of screening at
earlier ages in addition to later ages. For example, for the men aged
65–69 years at screening in our study, what would have been the
additional benefit of a screen 5 years earlier?
Our estimates were based on1544 PSA-detected cases, and on a
testing strategy that had a PSA cut-off of 3ngml
 1 and 10-core
biopsy. Though there is no screening programme in the United
Kingdom, there is ad hoc PSA testing (Pashayan et al, 2006). Thus,
our incidence data also included patients diagnosed by PSA
testing, although not in the context of formal screening. Incidence
data depend on the frequency of PSA testing, prostate biopsy, and
the biopsy protocol. Despite these limitations, our estimates are
broadly comparable to published estimates derived from Europe
and the United States of America.
In the absence of a screening programme and ongoing ad hoc
PSA testing in the United Kingdom, our findings give indications
to the natural history of prostate cancer and have implications for
design of demonstration projects and research studies, pending the
results from randomised controlled screening trials. Our results
indicate that for men aged 50–69 years, the MST does not vary
with age. The proportion of cases that can be detected by screening
increases with age. However, the benefit of screening in reducing
advanced stage disease is limited by overdiagnosis, which is
greater at older ages.
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Description of the studies used to derive age-specific sensitivity of PSA test
Paper Age Study size
PSA cut-off
(ngml
 1)
Sensitivity
% Study setting
Stenman et al (1994) Retrospective analysis of serum PSA in case–control study (Finland)
54 5912 3 58
71 1292 3 55
54 5912 4 58
71 1292 4 55
el-Galley et al (1995) Linking PSA to prostate biopsy data (USA)
45 168 4 20
55 868 4 80
65 1929 4 84
75 1402 4 87
Hoffman et al (2002) Community-based, linking PSA to prostate biopsy in ROC analysis (USA)
55 466 3 89
75 825 3 93
65 1153 3 89
65 1153 3 89
75 825 4 90
45 176 4 75
65 1153 4 84
Mistry and Cable (2003) Meta-analysis
Bretton (1994) 65 1027 4 67 Community-based study linking PSA to prostate biopsy data (USA)
Jubelirer et al (1994) 68 142 4 100 Community based study with 1-year follow-up (USA)
Imai et al (1994) 64 1680 4 73 Mass screening with PSA (Japan)
Imai et al (1995) 65 3276 4 80 Mass screening with PSA (Japan)
Higashihara et al (1996) 71 701 4 92 Clinical trial – ROC analysis (Japan)
Gustafsson et al (1998) 63 1782 4 80 PSA offered to randomly selected men (Sweden)
Brett (1998) 65 211 4 67 General-practice-based linking PSA to prostate biopsy result (Australia)
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